In this study, we found diverse clinical and antibody response between the COVID-19 severe group and non-severe group, mainly on antibody isotype and IgG titers, antibody specificity and dynamics, RBD-ACE2 blocking activity, FcγR binding capacity, B cell activation factor, and cytokines. This evidence concerns the gene ACE2 and COVID-19.